As an important risk factor for cardiovascular disease, diabetes mellitus has gradually received clinical attention in recent years. Data show that the risk of cardiovascular disease in diabetic patients is 2~4 times that of the general population, and the prevalence of diabetes in patients with coronary heart disease in mainland China is about 52.9%.
Seeing this, many people have to ask: Isn't diabetes an increase in blood sugar, and what is the relationship between blood sugar and cardiovascular disease?
The blood vessels of healthy people are like an unobstructed road, and blood, oxygen and nutrients can pass smoothly, but too high blood sugar will promote the formation of plaque, bring damage to the vascular endothelium, and platelets are easy to coagulate in the damaged parts, and then form blood clots; In addition, abnormal glucose metabolism will affect the synthesis and decomposition of lipids, causing blood lipid disorders, and "bad cholesterol" is also easy to be deposited under the vascular endothelium, resulting in atheromatous plaques and inducing cardiovascular diseases.
This is also a reminder to everyone: we must control blood sugar well, not only to prevent diabetes, but also to prevent cardiovascular disease. Especially for friends who are in the pre-diabetic stage - "metabolic syndrome", we should pay more attention in life!
Metabolic syndrome does not refer to a single disease, but a group of clinical symptoms determined by genetic factors and environmental factors, and important risk factors for diabetes and cardiovascular and cerebrovascular diseases such as central obesity, insulin resistance, abnormal glucose metabolism, hypertension, and dyslipidemia are common manifestations of metabolic syndrome.
As early as 1991, United States cardiologist Eugene Braunwald proposed the concept of "cardiovascular event chain" (metabolic syndrome→ arteriosclerosis→ acute myocardial infarction→ arrhythmias→ heart failure → death) (cardiovascular continuum), and he integrated metabolic syndrome and cardiovascular and cerebrovascular diseases into a complete chain. Studies have found that early intervention in the metabolic syndrome stage can effectively reduce the risk of diabetes and cardiovascular disease!
There are many ways to intervene early, such as eating a reasonable diet, controlling weight, increasing physical activity, quitting smoking and alcohol, etc. In terms of medicines, innovative Chinese medicine is playing an increasingly important role due to its advantages of focusing on holistic regulation.
Recently, the international medical journal ·United States JAMA Internal Medicine (impact factor 39) published a paper entitled "The Preventive Effect of Jinlida on Diabetes in People with Glucose Tolerance Disorders with Multiple Metabolic Disorders - FOCUS Randomized Clinical Trial", which introduced the role of the innovative Chinese medicine Jinlida in the intervention of patients with impaired glucose tolerance in metabolic syndrome.
This study adopted a randomized, double-blind, placebo parallel-controlled, multicenter design method, and included a total of 889 subjects aged 18~70 years old, with impaired glucose tolerance and abdominal obesity, accompanied by abnormal indicators of metabolic syndrome.
They were randomly assigned to the 1:1 ratio of zinlida and placebo, and on the basis of receiving standardized lifestyle interventions (including dietary modification and physical activity), they were given zinlida or placebo at a dose of 1 bag/time and 3 times/day. After some time in the experiment, the subject's state changed:
Compared with the placebo group, the risk of developing diabetes was reduced by 41% in the Jinlida group; They also experienced significant improvement in a number of metabolic abnormalities (e.g. waist circumference, body mass index, fasting and 2-hour postprandial blood glucose, glycosylated hemoglobin, total cholesterol, LDL cholesterol, and triglycerides). There are also significant differences in the key indicators of arteriosclerosis, brachial ankle index and carotid artery intimal thickness, which also confirms that the reasonable application of Jinlida on the basis of lifestyle intervention for people with glucose tolerance for abdominal obesity and other metabolic index disorders can reduce the risk of diabetes and try to kill the "symptoms" of cardiovascular event chain.
In the alleviation of type 2 diabetes and prediabetes symptoms, Jinlida can also play a more important role: it can protect pancreatic β cells, reduce islet β apoptosis, reduce insulin resistance, and regulate glucose and lipid metabolism disorders on this basis, and treat the root of diabetes. For patients with type 2 diabetes, it can also improve symptoms such as dry mouth, thirst, constipation, and fatigue, promote blood sugar targets, and reduce the occurrence of diabetes complications.
If you want to prevent diabetes and cardiovascular disease, it is also necessary to protect yourself in your daily life. Even if there is only one symptom of metabolic disorder, everyone should be vigilant, seek medical attention in time, and don't joke about health.